Clinical trial
Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment…
NCT00239239 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00239239 |
|---|---|
| Title | Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies |
| Official title | An Open-label, Single-arm Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Darbepoetin Alfa Administered Three Times Per Week for the Treatment of Anemia in Subjects With Non-myeloid Malignancies Receiving Multicycle Chemotherapy |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Myeloid Malignancies, Anemia, Cancer |
| Intervention type | Drug |
| Interventions | Darbepoetin alfa |
| Enrollment | 44 |
| Start date | Aug 1, 2005 |
| Primary completion | Jan 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Oct 17, 2005 |
| Last update posted | Mar 5, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: